USTEKINUMAB (Stelara) prior authorization at Horizon Blue Cross Blue Shield of New Jersey
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey requires Interleukin-12 Antagonist prior-authorization documentation for USTEKINUMAB (Stelara): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Horizon Blue Cross Blue Shield of New Jersey reviews USTEKINUMAB (Stelara) prior authorizations against its medical policy for Interleukin-12 Antagonist. Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-12 Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Horizon Blue Cross Blue Shield of New Jersey's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- OMNIA tier-1 vs tier-2 provider disputes
- Step therapy on biologics
- Behavioral health prior auth
- Out-of-state emergency reductions
USTEKINUMAB (Stelara)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring TNF-inhibitor first (plaque psoriasis, PsA, Crohn's, UC)
- Site-of-care reduction for IV induction dose
- Biosimilar substitution mid-treatment
- Prior auth missing PASI or HBI documentation
Brand: Stelara. IL-12/23 inhibitor. Loss of exclusivity 2023; FDA-approved biosimilars now include Wezlana (interchangeable), Selarsdi, Pyzchiva, Imuldosa, Otulfi, Steqeyma. Plans aggressively switching to biosimilar in 2025.
Manufacturer patient-assistance program: Janssen CarePath — relevant when a Horizon Blue Cross Blue Shield of New Jersey denial sticks and the patient needs bridge access while appealing.
How Horizon Blue Cross Blue Shield of New Jersey approaches Biologic drugs (mAbs and biosimilars) PAs
For USTEKINUMAB (YESINTEK), check whether the current Horizon Blue Cross Blue Shield of New Jersey Biologic drugs (mAbs and biosimilars) policy cites step therapy on biologics. Pharmacy-benefit review for USTEKINUMAB (YESINTEK) at Horizon Blue Cross Blue Shield of New Jersey is routed through Prime Therapeutics. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Horizon Blue Cross Blue Shield of New Jersey; if denied, use the filing date and route printed on that denial notice. Horizon Blue Cross Blue Shield of New Jersey's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Horizon Blue Cross Blue Shield of New Jersey is domiciled in NJ, so unresolved appeals escalate to the NJ insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.horizonblue.com/providers) with the same packet plus an applicable, current clinical source supporting USTEKINUMAB (Stelara)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Horizon Blue Cross Blue Shield of New Jersey denial on DenialHelp.
Contact Horizon Blue Cross Blue Shield of New Jersey
- Provider portal: https://www.horizonblue.com/providers
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for USTEKINUMAB (Stelara) prior auth?
Horizon Blue Cross Blue Shield of New Jersey's typical PA packet for USTEKINUMAB (Stelara): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-12 Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Horizon Blue Cross Blue Shield of New Jersey?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for USTEKINUMAB (Stelara) at Horizon Blue Cross Blue Shield of New Jersey?
Preparation scenarios to check against the current notice and policy include: OMNIA tier-1 vs tier-2 provider disputes; Step therapy on biologics; Behavioral health prior auth. These are not measured frequency claims. For USTEKINUMAB (Stelara), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Horizon Blue Cross Blue Shield of New Jersey typically require before approving USTEKINUMAB (YESINTEK)?
Horizon Blue Cross Blue Shield of New Jersey's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For USTEKINUMAB (YESINTEK), attach the specific disease-activity instrument Horizon Blue Cross Blue Shield of New Jersey accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Horizon Blue Cross Blue Shield of New Jersey fully-insured policies sits with the NJ insurance department.
How do I prep for a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey on USTEKINUMAB (Stelara)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Horizon Blue Cross Blue Shield of New Jersey
- Aflibercept at Horizon Blue Cross Blue Shield of New Jersey
- Apixaban at Horizon Blue Cross Blue Shield of New Jersey
- Atezolizumab at Horizon Blue Cross Blue Shield of New Jersey
- USTEKINUMAB (Stelara) at UnitedHealthcare
- USTEKINUMAB (Stelara) at Elevance Health
- USTEKINUMAB (Stelara) at Aetna
Generate the USTEKINUMAB (Stelara) PA packet
Open ApprovalHelp — generate a USTEKINUMAB (Stelara) prior-auth packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com